骨髓增生异常综合征小分子药物靶点治疗的研究进展
摘要
随着对骨髓增生异常综合征(MDS)发病机制的深入研究,小分子药物靶点治疗MDS已经取得了一定的进展。根除异常的细胞克隆和清除有利于MDS细胞生长的微环境是MDS治疗的主要目标。目前靶点治疗MDS的小分子药物主要有抗血管新生药物、法尼基转移酶抑制剂、格列卫、DNA甲基转移酶抑制剂、组蛋白去乙酰化酶抑制剂等。只有更深入地研究MDS的发病机制,才能使小分子药物靶点治疗 MDS取得更进一步的进展。
出处
《国外医学（输血及血液学分册）》
2005年第6期536-538,共3页
Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
参考文献20
-
1List AF, Vardiman J, Issa JP, et al. Myelodysplastic syndromes.Hematology (Am Soc Hematol Educ Program),2004,297-317.
-
2Mufti G, List AF, Gore SD, et al. Myelodysplastic syndromes.Hematology (Am Soc Hematol Educ Program),2003,176-199.
-
3Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001,98 (4):958-965.
-
4Moreno-Aspitia A, Geyer S, Li C, et al. N998B: multicenter phase Ⅱ trial of thalidomide (Thai) in adult patients with myelodysplastic syndromes (MDS). Blood ,2002,100 (11 ) : 96.
-
5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood ,2001,98(1) :210-216.
-
6Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia ormyelodysplastic syndromes. Blood,2003,102(11):795-801.
-
7Albitar M, Smolich BD, Cherrington JM, et al. Effects of SU5416 on angiogenic factors, proliferation and apoptosis in patients with hematological malignancies. Blood, 2001,98 ( 11 ) : 110.
-
8List AF, Schiller GJ, Mason J, et al. Trisenox (arsenic trioxide)in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase Ⅱ clinical study. Blood,2003,102 (2):423.
-
9Raza A, Lisak LA, Tahir S, et al. Trilineage responses to arsenic trioxide ( Trisenox ) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3) (q21q26.2). Blood ,2002,100(11) :795.
-
10Vey N, Dreyfus F, Guerci A, et al. Trisenox? (arsenic trioxide) in patients (pts) with myelodysplastic syndromes ( MDS ):Preliminary results of a phase 1/2 study, the 8th Congress of the European Hematology Association, Lyon, France, 2003,12-15.
-
1徐岚,沈志祥.骨髓增生异常综合征研究进展[J].世界临床药物,2005,26(8):477-480.
-
2许民,许莲蓉,乔振华.法尼基转移酶抑制剂的抗肿瘤作用机制及临床试验进展[J].国外医学（输血及血液学分册）,2005,28(4):356-360. 被引量：4
-
3赵谢兰,陈曙平,彭捷,刘弋,何群,陈方平.环孢素联合治疗骨髓增生异常综合征[J].中国新药与临床杂志,2003,22(5):295-298. 被引量：1
-
4刘昌发,陈精予.沙立度胺治疗骨髓增生异常综合征疗效观察[J].中国医药指南,2009,7(21):68-69.
-
5DAA小分子药物开创全口服治疗丙型肝炎新纪元[J].中华临床感染病杂志,2015,8(1):69-69.
-
6陈海平,马宾.组蛋白去乙酰化酶抑制剂在慢性心力衰竭中的作用及研究进展[J].心血管病学进展,2012,33(4):541-544.
-
7屈凌波,郭宗儒.法尼基转移酶抑制剂的研究进展[J].中国药物化学杂志,1998,8(4):305-310. 被引量：3
-
8静雨.小分子的抗艾滋病药物[J].国外医学情报,2001,22(8):34-34.
-
9陈轩,李华萍.组蛋白去乙酰化酶抑制剂在糖尿病治疗中的作用[J].上海交通大学学报（医学版）,2012,32(12):1641-1645. 被引量：2
-
10蔡博,柳柏林,高春记.组蛋白去乙酰化酶抑制剂在多发性骨髓瘤治疗中的研究进展[J].解放军医学院学报,2013,34(5):529-530. 被引量：2
